MedTrace Logo

AZD6765 Severe Major Depressive Disorder (MDD) IV

NCT00781742 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2012-07-25

No results posted yet for this study

Summary

The purpose of this research study is to determine whether AZD6765 has an effect on the patient's depression when taken together with current depression medication. In addition, information will be gathered on how well AZD6765 is tolerated, investigate the levels of AZD6765 and the levels of the current depression medication in the blood. In addition, the research staff will determine if AZD6765 has any mood or calming effects (how you feel).

Conditions

Interventions

DRUG

AZD6765

IV once per dosing day, multiple times during the treatment period

DRUG

Placebo

0.9% saline IV once per dosing day multiple times during the treatment period

Sponsors & Collaborators

Principal Investigators

  • Michael Castiglione · AstraZeneca

  • Gerard Sanacora · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00781742 on ClinicalTrials.gov